Opioid use disorder and dementia risk: evidence from observational and genetic analyses in diverse ancestry cohorts.

Javidnia S., Roe JM., Karhunen V., Gill D., Bell S., Deak JD., Levey D., Kember RL., Kranzler HR., Cronjé HT., Burgess S., Gelernter J., Ebmeier KP., Topiwala A.

INTRODUCTION: Opioid use disorder (OUD) may adversely affect brain health, but its role in dementia risk remains poorly understood. METHODS: We investigated associations between OUD and dementia using observational data from 222,518 participants (European and African ancestry) in the Million Veteran Program and Mendelian randomization (MR) using genome-wide association study summary statistics from 6,066,918 individuals. Polygenic risk score (PRS) analyses were conducted in 229 opioid-naïve Lifebrain consortium participants with longitudinal magnetic resonance imaging data. RESULTS: OUD was associated with increased risk of all-cause dementia (hazard ratio = 1.56, 95% confidence interval [CI]: 1.39 to 1.76), Alzheimer's disease, and vascular dementia. MR supported a potential causal link between genetic liability to OUD and dementia (inverse variance weighted odds ratio = 1.77, 95% CI: 1.43 to 2.19). Genetic variation in the μ-opioid receptor gene was also associated with dementia risk. No PRS associations were found with brain structure. DISCUSSION: These findings suggest a potential causal role for OUD in dementia, implicating μ-opioid receptor pathways in neurodegeneration.

DOI

10.1002/alz.71418

Type

Journal article

Publication Date

2026-05-01T00:00:00+00:00

Volume

22

Keywords

Mendelian randomization, dementia, neurodegeneration, opioid use disorder, polygenic risk score, Humans, Genome-Wide Association Study, Opioid-Related Disorders, Male, Female, Dementia, Mendelian Randomization Analysis, Magnetic Resonance Imaging, White People, Aged, Genetic Predisposition to Disease, Receptors, Opioid, mu, Risk Factors, Cohort Studies, Middle Aged, Polymorphism, Single Nucleotide, White

Permalink More information Close